BioAge Labs has broadened its APJ agonist development efforts by introducing two novel therapeutic candidates, according to the company. The first is azelaprag, an oral small‑molecule APJ agonist aimed at treating obesity. Azelaprag follows encouraging preclinical results announced in 2022, showing sustained receptor activity and potential metabolic benefits, the company said.
The second candidate is a long‑acting biologic APJ agonist, designed to provide extended duration of action. BioAge has secured an option agreement with JiKang Therapeutics in Asia‑Pacific to advance this biologic through preclinical development into clinical stages, the company said. While financial details of the JiKang partnership were not disclosed, the agreement expands BioAge’s translational reach in key international markets.
According to BioAge, the dual‑modality pipeline complements its existing programs, reinforcing the APJ agonist platform across both small molecule and biologic modalities. The small‑molecule approach offers the convenience of oral dosing, whereas the biologic option may enable less frequent administration with potentially improved patient compliance.
BioAge claims the expanded pipeline strengthens its leadership in targeting the APJ receptor, which is implicated in regulating metabolic health and aging. The company said this strategic move aligns with its broader mission to develop longevity‑focused therapies with global impact.
